The DYNLL2 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function investigations of the DYNLL2 gene. This product consists of a genetically heterogeneous pool of HAP1 cells carrying targeted disruptions in DYNLL2, enabling robust functional studies without the need for single-cell cloning. The polyclonal format minimizes clonal artifacts and provides immediate experimental access to a diverse knockout population, facilitating rapid phenotypic screening.
HAP1 is a near-haploid, adherent human cell line derived from the KBM-7 chronic myeloid leukemia line. Its near-haploid karyotype simplifies genome editing and genetic analysis, establishing HAP1 as a standard platform for genome-wide knockout screens and functional genomics. These cells retain core pathways relevant to cancer biology and intracellular transport, offering a physiologically relevant setting to examine DYNLL2-dependent processes.
DYNLL2 encodes a light chain subunit of the cytoplasmic dynein motor complex, mediating minus-end-directed transport along microtubules. In a separate, motor-independent role, DYNLL2 directly binds and inhibits the pro-apoptotic BH3-only protein Bim (BCL2L11), thereby suppressing mitochondrial outer membrane permeabilization and apoptosis. This interaction is disrupted by apoptotic stimuli, unleashing Bim to activate BAX/BAK and commit cells to death. DYNLL2 also interacts with dynein intermediate chains, DYNLL1, p53-binding protein 1, and members of the BCL2 family, positioning it at the intersection of intracellular trafficking, cell survival, and cell cycle regulation.
In the HAP1 background, DYNLL2 knockout provides a simplified genetic system to dissect its dual functions in transport and apoptosis. The near-haploid nature ensures efficient target-gene disruption with minimal genetic redundancy, while the leukemic origin of HAP1 offers a cancer-relevant context for studying oncogenic survival mechanisms. This model enables researchers to investigate how loss of DYNLL2 impacts dynein-mediated organelle positioning and sensitizes cells to apoptotic triggers, with potential implications for neurodegenerative diseases where dynein dysfunction is a hallmark.
This DYNLL2 polyclonal knockout model is compatible with a broad panel of assays to characterize molecular and cellular phenotypes. Western blotting and quantitative proteomics can confirm DYNLL2 depletion and changes to interacting partners such as Bim and dynein subunits. Co-immunoprecipitation experiments reveal altered protein?Cprotein interactions, while apoptosis assays including Annexin V/7-AAD staining measure cell death kinetics. Immunofluorescence and live-cell imaging enable visualization of cargo trafficking defects, and flow cytometry facilitates high-throughput phenotypic screening. Researchers studying dynein-dependent transport, apoptosis regulation, or cancer cell survival will find these knockout cells indispensable. For additional information or custom requests, please contact Ascent Research.
